Monday , January 25 2021

Specialty Pharma Journal Specialty, Precision & Technology

Breaking News

FDA Approves Gavreto for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM
Natera Announces SMART Study Data for Aneuploidy and 22q Unblinded
Aimmune Agrees to be Acquired by Nestlé Health Science for $2 Billion
Twist Bioscience Announces Potent SARS-CoV-2 Neutralizing Data from COVID-19 Therapeutic Antibody Program
Final Analysis of the Observational GioTag Study: Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive NSCLC
Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications
FDA Approves Onureg, a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
FDA Accepts Vertex’s sNDA for Trikafta, Symdeko and Kalydeco for Additional CFTR Mutations
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

Tag Archives: ALS Finding a Cure

July, 2016

20 July
ALS Association and ALS Finding a Cure Provide Funding for Amylyx’s Mid-Stage Combo Trial

Washington, D.C. and Cambridge, Mass. (July 20, 2016) — The ALS Association and Amylyx Pharmaceuticals based in Cambridge, Mass. are pleased to announce that The ALS Association and ALS Finding a Cure® are jointly providing funding to support a Phase II trial of a potential new therapeutic approach being developed …
Share

February, 2016

10 February
$1 Million Investment to Launch Grand Challenge to Develop a TDP43 Biomarker for ALS

WASHINGTON, Feb. 10, 2016 /PRNewswire-USNewswire/ — The ALS Association, in partnership with ALS Finding a Cure, is pleased to announce the Grand Challenge to generate a biomarker to track TDP43 aggregation. The successful team(s) with the most developed plan will receive up to a $1 million investment. ALS is a progressive …
Share